FibroBiologics Q3 2026 Earnings Date & Estimates

FibroBiologics (NASDAQ:FBLG), Inc. is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research focuses on fibroblasts, connective-tissue cells that may support tissue repair and influence immune-system activity, as well as biologically active materials derived from these cells.

The company is developing a platform that includes fibroblast-based cell therapies and fibroblast-derived extracellular vesicles. These potential treatments are intended to address conditions involving chronic inflammation, immune dysfunction, and tissue damage. FibroBiologics has identified potential applications in diseases such as psoriasis, multiple sclerosis, and other chronic disorders, although its programs remain in development and require further clinical testing.

FibroBiologics became a publicly traded company through a business combination and trades on the Nasdaq under the symbol FBLG. The company is based in the United States and is focused primarily on advancing its research and development programs through preclinical and clinical studies. Its therapies have not been broadly approved for commercial use, and the timing and outcome of future development efforts remain subject to regulatory and clinical uncertainty.